{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:33:02Z","timestamp":1792427582451,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2015\/19\/B\/NZ7\/02847"],"award-info":[{"award-number":["2015\/19\/B\/NZ7\/02847"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Memantine is used in Alzheimer\u2019s disease treatment as a non-competitive modern-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist. The fundamental role of these receptors is to bind glutamate: the main excitatory neurotransmitter in the brain, believed to play a crucial role in neuronal plasticity and learning mechanisms. Glutamate transmission plays an important role in all internal CNS structures and maintains the physiological state of the brain. Excessive glutamate transmission can lead to enlarged calcium ion current which may cause neurotoxicity; however, insufficient transmission can drastically alter the information flow in neurons and the brain, potentially causing schizophrenia-like symptoms by replacing lost information with completely new stimuli. Hence, it is possible that the modulation of NMDA activity may give rise to pathophysiological states. Available literature and clinical trials indicate that memantine is well tolerated by patients, with very few and light side effects. There is a belief that memantine may also benefit other conditions such as schizophrenia and depression.<\/jats:p>","DOI":"10.1007\/s00109-020-01982-z","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T21:03:27Z","timestamp":1610658207000},"page":"327-334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Memantine in neurological disorders \u2013 schizophrenia and depression"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-1565","authenticated-orcid":false,"given":"Kamila","family":"Czarnecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Chuchmacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"W\u00f3jtowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-7509","authenticated-orcid":false,"given":"Pawe\u0142","family":"Szyma\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"issue":"22","key":"1982_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJM199911253412207","volume":"341","author":"R Mayeux","year":"2003","unstructured":"Mayeux R, Sano M (2003) Treatment of Alzheimer\u2019s disease. N Engl J Med 341(22):1670\u20131679","journal-title":"N Engl J Med"},{"key":"1982_CR2","unstructured":"M Prince, E Albanese, M Guerchet, M Prina (2014) World Alzheimer report 2014, dementia and risk reduction and analysis or protective and modifiable factors, Chap. 1, p. 6\u201310, https:\/\/www.alz.co.uk\/research\/world-report-2014. Accessed 1 Jun 2020"},{"key":"1982_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM (2018) Alzheimer\u2019s disease. Eur J Neurol 25:59\u201370","journal-title":"Eur J Neurol"},{"issue":"15","key":"1982_CR4","first-page":"00092","volume":"S1474\u20134422","author":"Y-T Wu","year":"2015","unstructured":"Wu Y-T, Fratiglioni L, Matthews FE, Lobo A, Breteler MMB, Skoog I, Brayne C (2015) Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol S1474\u20134422(15):00092\u201300097","journal-title":"Lancet Neurol"},{"key":"1982_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4088\/JCP.17f11998","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C (2017) Memantine as an augmentation treatment for schizophrenia, limitations of meta- analysis for evidence based evaluation of research. J Clin Psychiatry 78:9","journal-title":"J Clin Psychiatry"},{"key":"1982_CR6","unstructured":"M. Prince, A. Wimo, M. Guerchet, G.C. Ali, Y.T. Wu, M. Prina (2015) World Alzheimer report 2015, the global impact of dementia, an analysis of prevalence, incidence costs and trends, Chap. 2, p. 10\u201325, www.alz.co.uk\/worldreport2015corrections. Accessed 1 Jun 2020"},{"key":"1982_CR7","doi-asserted-by":"crossref","unstructured":"Matthews FE, Stephan BCM, Robinson L, Jagger C, Barnes LE, Arthur A, Brayne C A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nat Commun 7:11398","DOI":"10.1038\/ncomms11398"},{"key":"1982_CR8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/S0140-6736(12)61803-0","volume":"380","author":"C Brayne","year":"2012","unstructured":"Brayne C, Davis D (2012) Making Alzheimer\u2019s and dementia research fi t for populations. Lancet 380:1441\u20131443","journal-title":"Lancet"},{"key":"1982_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1474-4422(05)70286-6","volume":"5","author":"LJ Whalley","year":"2006","unstructured":"Whalley LJ, Dick FD, McNeill G (2006) A life-course approach to the aetiology of late-onset dementias. Lancet Neurol 5:87\u201396","journal-title":"Lancet Neurol"},{"key":"1982_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMp1311405","volume":"369","author":"EB Larson","year":"2013","unstructured":"Larson EB, Yaffe K, Langa KM (2013) New insights into the dementia epidemic. N Engl J Med 369:24","journal-title":"N Engl J Med"},{"key":"1982_CR11","doi-asserted-by":"crossref","unstructured":"Hardy J, Selkoe DJ The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297(5580):353\u2013356","DOI":"10.1126\/science.1072994"},{"key":"1982_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ca.980080612","volume":"8","author":"RA Stelzma","year":"1995","unstructured":"Stelzma RA, Schnitzlein HN, Muriagh FR (1995) An English translation of Alzheimer\u2019s 1907 paper, \u201cUber eine eigenartige Erlranliung der Hirnrinde\u201d. Clin Anat 8:429\u201343 1 https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ca.980080612","journal-title":"Clin Anat"},{"key":"1982_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt107","volume":"4","author":"S Weggen","year":"2012","unstructured":"Weggen S, Beher D (2012) Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer\u2019s disease. Alzheimers Res Ther 4:9","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"1982_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"C Liu","year":"2013","unstructured":"Liu C, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. Nat Rev Neurol 9(2):106\u2013118","journal-title":"Nat Rev Neurol"},{"key":"1982_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(10)70325-2","volume":"10","author":"PB Verghese","year":"2011","unstructured":"Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in Alzheimer\u2019s disease and other neurological disorders. Lancet Neurol 10:241\u2013252","journal-title":"Lancet Neurol"},{"key":"1982_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.biopsych.2014.05.006","volume":"77","author":"CM Karch","year":"2015","unstructured":"Karch CM, Goate AM (2015) Alzheimer\u2019s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 77:43\u201351","journal-title":"Biol Psychiatry"},{"issue":"2","key":"1982_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrd1311","volume":"3","author":"A Witt","year":"2004","unstructured":"Witt A, Macdonald N, Kirkpatrick P (2004) Memantine hydrochloride. Nat Rev Drug Discov 3(2):109\u2013110","journal-title":"Nat Rev Drug Discov"},{"key":"1982_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","volume":"38","author":"CG Parsons","year":"1999","unstructured":"Parsons CG, Danysz W, Quack G (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist\u2014a review of preclinical data. Neuropharmacology 38:735\u2013767","journal-title":"Neuropharmacology"},{"key":"1982_CR19","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1021\/jm00342a029","volume":"6","author":"K Gerzon","year":"1963","unstructured":"Gerzon K, Krumkalns EV, Brindle RL, Marshall FJ, Root MA (1963) The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N'-adamantylureas. J Med Chem 6:760\u2013763","journal-title":"J Med Chem"},{"key":"1982_CR20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nn936","volume":"5 Suppl","author":"JA Kemp","year":"2002","unstructured":"Kemp JA, McKernan RM (2002) NMDA receptor pathway as drug target. Nat Neurosci 5 Suppl:1039\u20131042","journal-title":"Nat Neurosci"},{"key":"1982_CR21","first-page":"7021071","volume":"2017","author":"GD Lorio","year":"2017","unstructured":"Lorio GD, Baroni G, Lorusso M, Montemitro C, Chiara Spano M, Giannantonio MD (2017) Efficacy of memantine in schizophrenic patients: a systematic review. J Amino Acids 2017:7021071\u20137021076","journal-title":"J Amino Acids"},{"key":"1982_CR22","unstructured":"Vetulani J (2004) Memantine \u2013 hope for treatment of dementia and other neurodegenerative disorders. Psychogeriatr Pol 1:39\u201350 https:\/\/docplayer.pl\/6365034-Jerzy-vetulani-psychogeriatr-pol-2004-1-39-50-streszczenie-praca-pogl1dowa-review-paper-pgp-6-issn-1732-2642.html. Accessed 1 Jun 2020"},{"key":"1982_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.brainresbull.2010.04.006","volume":"83","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Javitt DC (2010) N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 83:108\u2013121","journal-title":"Brain Res Bull"},{"key":"1982_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1177\/0269881106073126","volume":"21","author":"JM Stone","year":"2007","unstructured":"Stone JM, Morrison PD (2007) Glutamate and dopamine dysregulation in schizophrenia \u2013 a synthesis and selective review. J Psychopharmacol 21:440\u2013452","journal-title":"J Psychopharmacol"},{"issue":"3","key":"1982_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s10943-012-9673-y","volume":"53","author":"MK Irmak","year":"2014","unstructured":"Irmak MK (2014) Schizophrenia or possesion? J Relig Health 53(3):773\u2013777","journal-title":"J Relig Health"},{"key":"1982_CR26","first-page":"384783","volume":"2014","author":"A Paraschakis","year":"2014","unstructured":"Paraschakis A (2014) Tackling negative symptoms of schizophrenia with memantine. Case Rep Psychiatry 2014:384783\u2013384783","journal-title":"Case Rep Psychiatry"},{"key":"1982_CR27","doi-asserted-by":"publisher","unstructured":"Coyle JT (2006, 2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26(4\u20136). https:\/\/doi.org\/10.1007\/s10571-006-9062-8","DOI":"10.1007\/s10571-006-9062-8"},{"issue":"10039","key":"1982_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen MJ, Sawa A, Mortensen PB (2016) Schizophrenia. Lancet. 388(10039):86\u201397","journal-title":"Lancet."},{"issue":"3","key":"1982_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/JCP.0b013e31828b50a7","volume":"33","author":"F Rezaei","year":"2013","unstructured":"Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S (2013 Jun) Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 33(3):336\u2013342","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1982_CR30","first-page":"108","volume":"45","author":"V Omranifard","year":"2017","unstructured":"Omranifard V, Rajabi F, Mohammadian-Sichani M, Maracy MR (2017) The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: a doubleblind, randomized, controlled trial. Actas Esp Psiquiatr 45(3):108\u2013115","journal-title":"Actas Esp Psiquiatr"},{"key":"1982_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1055\/s-0034-1385931","volume":"47","author":"JP John","year":"2014","unstructured":"John JP, Lukose A, Manjunath S (2014) Off -label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. Pharmacopsychiatry 47:202\u2013209","journal-title":"Pharmacopsychiatry"},{"issue":"11","key":"1982_CR32","first-page":"696","volume":"54","author":"A Fakhri","year":"2016","unstructured":"Fakhri A, Pakseresht S, Reza Haghdoost M, Hekmatkhah N, Torkashv M, Ghorbanzadeh B (2016) Memantine enhances the effect of olanzapine in patients with schizophrenia: a randomized, placebo-controlled study. Acta Medica Iranica 54(11):696\u2013703","journal-title":"Acta Medica Iranica"},{"key":"1982_CR33","unstructured":"Stahl S (2008) \u201cAntipsychotic agents.\u201d In Stahl\u2019s essential psychophar- macology, pp. 440\u2013446, Cambridge University Press, 3rd edi- tion"},{"issue":"1\u20132","key":"1982_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0304-3940(01)01872-9","volume":"306","author":"G Rammesa","year":"2001","unstructured":"Rammesa G, Rupprechta R, Ferraria U, Zieglga\u00e8nsbergera W, Parsons CG (2001) The N-methyl-d-aspartate receptor channel blockers memantine, (2001) MRZ 2\/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 306(1\u20132):81\u201384","journal-title":"Neurosci Lett"},{"issue":"2","key":"1982_CR35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1345\/aph.1G297","volume":"40","author":"SS Carpenter","year":"2006","unstructured":"Carpenter SS, Hatchett AD, Fuller MA (2006) Catatonic schizophrenia and the use of memantine. (2005). Ann Pharmacother 40(2):344\u2013346","journal-title":"Ann Pharmacother"},{"issue":"5","key":"1982_CR36","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/npp.2008.200","volume":"34","author":"JA Lieberman","year":"2008","unstructured":"Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A (2008) A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34(5):1322\u20131329","journal-title":"Neuropsychopharmacology"},{"issue":"14","key":"1982_CR37","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00213-017-4616-7","volume":"234","author":"T Kishi","year":"2017","unstructured":"Kishi T, Matsuda Y, Iwata N (2017) Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology 234(14):2113\u20132125","journal-title":"Psychopharmacology"},{"issue":"8","key":"1982_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1176\/appi.ajp.2016.15121509","volume":"173","author":"KS Kendler","year":"2016","unstructured":"Kendler KS (2016) The phenomenology of major depression and the representativeness and nature of DSM criteria. Am J Psychiatry 173(8):771\u2013780","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1982_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/10673220500174833","volume":"13","author":"K Trede","year":"2005","unstructured":"Trede K, Salvatore P, Baethge C, Gerhard A, Maggini C, Baldessarini RJ (2005) Manic-depressive illness: evolution in Kraepelin\u2019s textbook, 1883\u20131926. Harvard Rev Psychiatry 13(3):155\u2013178","journal-title":"Harvard Rev Psychiatry"},{"issue":"329","key":"1982_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1192\/bjp.80.329.277","volume":"80","author":"AJ Lewis","year":"1934","unstructured":"Lewis AJ (1934) Melancholia: a clinical survey of depressive states. J Ment Sci 80(329):277\u2013378","journal-title":"J Ment Sci"},{"issue":"6","key":"1982_CR41","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1176\/ajp.156.6.837","volume":"156","author":"KS Kendler","year":"1999","unstructured":"Kendler KS, Karkowski LM, Prescott CA (1999) Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 156(6):837\u2013841","journal-title":"Am J Psychiatry"},{"issue":"2003","key":"1982_CR42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1126\/science.1083968","volume":"301-386","author":"A Caspi","year":"2003","unstructured":"Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Polymorphism in the 5-HTT gene influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301-386(2003):386\u2013389","journal-title":"Science"},{"issue":"12","key":"1982_CR43","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/0004867415617657","volume":"49","author":"GS Malhi","year":"2015","unstructured":"Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, Hopwood M, Lyndon B, Mulder R, Murray G, Porter R, Singh AB (2015) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 49(12):1087\u20131206","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"1982_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0004867418824026","volume":"53","author":"BT Baune","year":"2019","unstructured":"Baune BT, Boyce P, Morris G, Hamilton A, Bassett D, Hopwood M, Mulder R, Parker G, Porter R, Singh AB, Outhred T, Das P, Malhi GS (2019) Organising the front line: is there a rationale for the first-line pharmacotherapy of major depressive disorder? Aust N Z J Psychiatry 53(4):279\u2013281","journal-title":"Aust N Z J Psychiatry"},{"issue":"10","key":"1982_CR45","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1080\/14656566.2017.1334765","volume":"18","author":"S Paolucci","year":"2017","unstructured":"Paolucci S (2017) Advances in antidepressants for treating post-stroke depression. Expert Opin Pharmacother 18(10):1011\u20131017","journal-title":"Expert Opin Pharmacother"},{"key":"1982_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bjop.12378","volume":"111","author":"L Psychogiou","year":"2019","unstructured":"Psychogiou L, Russell G, Owens M (2019) Parents\u2019 postnatal depressive symptoms and their children's academic attainment at 16 years: pathways of risk transmission. Br J Psychol 111:1\u201316","journal-title":"Br J Psychol"},{"issue":"2","key":"1982_CR47","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/1119-3077.196114","volume":"20","author":"JE Asuquo","year":"2017","unstructured":"Asuquo JE, Edet BE, Abang IE, Essien EA, Osakwe OG, Aigbomain EJ, Chigbundu KC (2017) Depression and posttraumatic stress disorder among road traffic accident victims managed in a tertiary hospital in Southern Nigeria. Niger J Clin Pract 20(2):170\u2013175","journal-title":"Niger J Clin Pract"},{"key":"1982_CR48","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1192\/bjp.113.504.1237","volume":"113","author":"A Coppen","year":"1967","unstructured":"Coppen A (1967) The biochemistry of Affectie disorders. Brit J Psychiat 113:1237\u20131264","journal-title":"Brit J Psychiat"},{"issue":"5","key":"1982_CR49","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1176\/ajp.122.5.509","volume":"122","author":"JJ Schildkraut","year":"1965","unstructured":"Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122(5):509\u2013522","journal-title":"Am J Psychiatry"},{"key":"1982_CR50","doi-asserted-by":"publisher","first-page":"3682752","DOI":"10.1155\/2017\/3682752","volume":"2017","author":"U Doboszewska","year":"2017","unstructured":"Doboszewska U, Wla\u017a P, Nowak G, Radziwo\u0144-Zaleska M, Cui R, M\u0142yniec K (2017) Zinc in the monoaminergic theory of depression: its relationship to neural plasticity. Neural Plast 2017:3682752","journal-title":"Neural Plast"},{"issue":"1","key":"1982_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163(1):28\u201340","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1982_CR52","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-170672","volume":"62","author":"J Folch","year":"2018","unstructured":"Folch J, Busquets O, Ettcheto M, S\u00e1nchez-L\u00f3pez E, Castro-Torres RD, Verdaguer E, Garcia ML, Olloquequi J, Casades\u00fas G, Beas-Zarate C, Pelegri C, Vilaplana J, Auladell C, Camins A (2018) Memantine for the treatment of dementia: a review on its current and future applications. J Alzheimers Dis 62(3):1223\u20131240","journal-title":"J Alzheimers Dis"},{"key":"1982_CR53","doi-asserted-by":"crossref","unstructured":"Krishnan V, Nestler EJ (2008, Nature) The molecular neurobiology of depression. 455(7215):894\u2013902","DOI":"10.1038\/nature07455"},{"issue":"8","key":"1982_CR54","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856\u2013864","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1982_CR55","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/00048670701787628","volume":"42","author":"R Kollmar","year":"2008","unstructured":"Kollmar R, Markovic K, Th\u00fcrauf N, Schmitt H, Kornhuber J (2008) Ketamine followed by memantine for the treatment of major depression. Aust N Z J Psychiatry 42(2):170","journal-title":"Aust N Z J Psychiatry"},{"issue":"10","key":"1982_CR56","doi-asserted-by":"publisher","first-page":"966","DOI":"10.4088\/JCP.12m08252","volume":"74","author":"EG Smith","year":"2013","unstructured":"Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ (2013) Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 74(10):966\u2013973","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1982_CR57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/jcpt.12469","volume":"42","author":"M Amidfar","year":"2017","unstructured":"Amidfar M, Khiabany M, Kohi A, Salardini E, Arbabi M, Roohi Azizi M, Zarrindast MR, Mohammadinejad P, Zeinoddini A, Akhondzadeh S (2017) Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. J Clin Pharm Ther 42(1):44\u201350","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"1982_CR58","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4088\/JCP.v69n0308","volume":"69","author":"LH Muhonen","year":"2008","unstructured":"Muhonen LH, L\u00f6nnqvist J, Juva K, Alho H (2008) Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 69(3):392\u2013399","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1982_CR59","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/sj.npp.1300252","volume":"28","author":"JH Krystal","year":"2003","unstructured":"Krystal JH, Petrakis IL, Limoncelli D, Webb E, Gueorgueva R, D'Souza DC, Boutros NN, Trevisan L, Charney DS (2003) Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology 28(11):2020\u20132028","journal-title":"Neuropsychopharmacology"},{"key":"1982_CR60","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/sj.npp.1300252","volume":"28","author":"J Krystal","year":"2003","unstructured":"Krystal J, Petrakis I, Limoncelli D et al (2003) Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacol 28:2020\u20132028","journal-title":"Neuropsychopharmacol"},{"key":"1982_CR61","unstructured":"Rog\u00f3z Z, Skuza G, Legutko B Repeated co-treatment with imipramine and amantadine induces hippocampal brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol 58(2):219\u2013234"},{"key":"1982_CR62","doi-asserted-by":"publisher","unstructured":"Amidfar M, R\u00e9us GZ, Quevedo J, Kim Y-K, Arbabi M (2017) Effect of co-administration of memantine and sertraline on the antidepressant-like activity and brain-derived neurotrophic factor (BDNF) levels in the rat brain. Brain Res Bull. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.11.003","DOI":"10.1016\/j.brainresbull.2016.11.003"},{"issue":"3","key":"1982_CR63","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/WNF.0b013e3180314ae7","volume":"30","author":"JM Ferguson","year":"2007","unstructured":"Ferguson JM, Shingleton RN (2007) An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 30(3):136\u2013144","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"1982_CR64","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/gps.4375","volume":"31","author":"GH Pelton","year":"2016","unstructured":"Pelton GH, Harper OL, Roose SP, Marder K, D\u2019Antonio K, Devanand DP (2016) Combined treatment with memantine\/es-citalopram for older depressed patients with cognitive impairment: a pilot study. Int J Geriatr Psychiatry 31(6):648\u2013655","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"1982_CR65","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40266-016-0434-6","volume":"34","author":"AH Ford","year":"2017","unstructured":"Ford AH, Almeida OP (2017) Management of depression in patients with dementia: is pharmacological treatment justified? Drugs Aging 34(2):89\u201395","journal-title":"Drugs Aging"},{"issue":"6","key":"1982_CR66","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.brainresbull.2009.11.013","volume":"81","author":"GZ R\u00e9us","year":"2010","unstructured":"R\u00e9us GZ, Stringari RB, Kirsch TR, Fries GR, Kapczinski F, Roesler R, Quevedo J (2010) Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull 81(6):585\u2013589","journal-title":"Brain Res Bull"},{"issue":"1","key":"1982_CR67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3233\/JAD-161251","volume":"57","author":"T Kishi","year":"2017","unstructured":"Kishi T, Matsunaga S, Iwata N (2017) A meta-analysis of memantine for depression. J Alzheimers Dis 57(1):113\u2013121","journal-title":"J Alzheimers Dis"},{"key":"1982_CR68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejphar.2018.03.023","volume":"827","author":"M Amidfar","year":"2018","unstructured":"Amidfar M, R\u00e9us GZ, Quevedo J, Kim YK (2018) The role of memantine in the treatment of major depressive disorder: clinical efficacy and mechanisms of action. Eur J Pharmacol 827:103\u2013111","journal-title":"Eur J Pharmacol"},{"key":"1982_CR69","doi-asserted-by":"publisher","unstructured":"Jeon SW, Kim Y-K (2017) Inflammation-induced depression: its pathophysiology and therapeutic implications. J Neur Immun. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.10.016","DOI":"10.1016\/j.jneuroim.2017.10.016"},{"key":"1982_CR70","doi-asserted-by":"publisher","unstructured":"Vasileva LV, Ivanovska MV, Murdjeva MA, Saracheva KE, Georgiev MI (2019, 2019) Immunoregulatory natural compounds in stress-induced depression: an alternative or an adjunct to conventional antidepressant therapy? Food Chem Toxicol. https:\/\/doi.org\/10.1016\/j.fct.2019.03.004","DOI":"10.1016\/j.fct.2019.03.004"},{"issue":"3","key":"1982_CR71","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nm.4050","volume":"22","author":"RS Duman","year":"2016","unstructured":"Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016) Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 22(3):238\u2013249","journal-title":"Nat Med"},{"issue":"1","key":"1982_CR72","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neuroscience.2010.04.035","volume":"169","author":"E Ampuero","year":"2010","unstructured":"Ampuero E, Rubio FJ, Falcon R, Sandoval M, Diaz-Veliz G, Gonzalez RE, Earle N, Dagnino-Subiabre A, Aboitiz F, Orrego F, Wyneken U (2010) Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 169(1):98\u2013108","journal-title":"Neuroscience"},{"issue":"5","key":"1982_CR73","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.bcp.2009.04.008","volume":"78","author":"GW Valentine","year":"2009","unstructured":"Valentine GW, Sanacora G (2009) Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol 78(5):431\u2013439","journal-title":"Biochem Pharmacol"},{"key":"1982_CR74","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1001\/archpsyc.60.7.664","volume":"60","author":"S Dennis","year":"2003","unstructured":"Dennis S et al (2003) Depression and Bipolar Support alliance Consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry 60:664\u2013672","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1982_CR75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.brainresrev.2009.05.005","volume":"61","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61(2):105\u2013123","journal-title":"Brain Res Rev"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-01982-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-020-01982-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-020-01982-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T05:23:21Z","timestamp":1674883401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-020-01982-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1982"],"URL":"https:\/\/doi.org\/10.1007\/s00109-020-01982-z","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"1 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}